Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.2752W HIGH $14.87
Volume
566.22 K
Value Traded
1.95 M
Short % Float
7.52%
-12.08%Week
-49.37%1 Month
-58.89%3 Month
-59.29%6 Month
-14.76%5 Year
-14.76%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
274.20 M
EPS (TTM)
-2.91
P/E Ratio
-
Ent. Value
-69.93 M
Total Shares
80.17 M
Float Shares
47.85 M
Insiders
40.32%
Institutions
54.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
BBOT Catalyst Timeline
Dated clinical, regulatory and corporate events for BridgeBio Oncology Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BridgeBio Oncology Therapeutics, Inc.
77Total events
15Upcoming
19Tier-1 (high impact)
2024 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutBBO-8520Clinical Data
BBO-8520 plus pembrolizumab 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRAS G12C inhibitor-experienced NSCLC
2L+ KRAS G12C inhibitor-experienced NSCLCsource ↗
●Enrollment UpdateBBO-11818Trial
BBO-11818 combination cohorts enrolling
KRAS-mutant CRC and PDACsource ↗
●Enrollment UpdateBBO-10203Trial
BBO-10203 combination cohorts enrolling
KRAS-mutant CRC and PDACsource ↗
▲Additional DataBBO-8520Clinical Data
BBO-8520 plus pembrolizumab data update: 75% ORR at 500 mg QD, 53% across dose levels
KRAS G12C inhibitor-experienced NSCLCsource ↗
●Pipeline PrioritizationCorporate
Strategic prioritization of BBO-8520 combination in 2L+ NSCLC and BBO-11818/BBO-10203 combinations in KRAS-mutant cancers
KRAS-mutant cancerssource ↗
◆Poster PresentationBBO-11818Presentation
Poster presentation on BBO-11818 at AACR 2026
KRAS-mutant solid tumorssource ↗
◆Oral PresentationBBO-10203Presentation
Oral presentation on BBO-10203 at AACR 2026
HER2+ breast cancer, HR+/HER2- breast cancer, KRAS-mutant colorectal cancer, KRAS-mutant non-small cell lung cancersource ↗
◆Management ChangeCorporate
Appointment of Pedro J. Beltran, PhD as CEO, Idan Elmelech as COO, and Neil Kumar, PhD as Executive Chairman
▲Trial InitiationBBO-8520Trial
Internal combination study of BBO-8520 with BBO-10203 opened
KRAS G12C non-small cell lung cancersource ↗
◆Topline ReadoutBBO-8520Clinical Data
Updated clinical data expected for BBO-8520
KRASG12C NSCLCsource ↗
◆Topline ReadoutBBO-11818Clinical Data
Updated clinical data expected for BBO-11818
advanced solid tumorssource ↗
◆Topline ReadoutBBO-10203Clinical Data
Updated clinical data expected for BBO-10203
advanced solid tumorssource ↗
◆Trial InitiationBBO-11818Trial
Internal combination trial of BBO-11818 with BBO-10203 anticipated to open
advanced solid tumorssource ↗
◆Trial InitiationBBO-10203Trial
Internal combination trials of BBO-10203 with BBO-8520 and BBO-11818 anticipated to open
advanced solid tumorssource ↗
▲PublicationBBO-11818Presentation
Publication of preclinical data for BBO-11818 in Cancer Discovery
KRAS mutant solid tumorssource ↗
◆Oral PresentationPresentation
Company webcast to discuss data updates for BBO-8520, BBO-11818, and BBO-10203
▲Topline ReadoutBBO-8520Clinical Data
Preliminary safety and efficacy data for BBO-8520 monotherapy and with pembrolizumab announced
KRAS G12C non-small cell lung cancersource ↗
▲Topline ReadoutBBO-11818Clinical Data
Preliminary clinical data for BBO-11818 showing PR in pancreatic cancer
advanced solid tumorssource ↗
▲Topline ReadoutBBO-10203Clinical Data
Preliminary safety and PK data for BBO-10203 monotherapy; recommended dose identified
HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, KRAS mutant NSCLCsource ↗
▲Dose Finding UpdateBBO-10203Trial
Recommended go-forward dose of 500 mg QD identified for BBO-10203
HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, KRAS mutant NSCLCsource ↗
▲Trial InitiationBBO-10203Trial
Combination cohorts initiated for BBO-10203 with standard-of-care treatments
HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, KRAS mutant NSCLCsource ↗
●Enrollment UpdateBBO-8520Trial
Patients enrolled across doses 100 mg to 700 mg QD
KRAS G12C mutant NSCLCsource ↗
●Enrollment UpdateBBO-11818Trial
Patients enrolled across dose levels 50 mg to 800 mg BID
KRAS mutant solid tumorssource ↗
●Enrollment UpdateBBO-10203Trial
24 patients enrolled in monotherapy portion across doses 150 mg to 750 mg QD
HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, KRAS mutant NSCLCsource ↗
▲Topline ReadoutBBO-11818Clinical Data
Initial Phase 1 monotherapy data announced
KRAS mutant solid tumorssource ↗
◆Poster PresentationBBO-10203Presentation
Trial in progress poster on Phase 1 BREAKER-101 trial at SABCS
locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, KRAS mutant non-small cell lung cancersource ↗
◆Poster PresentationBBO-10203Presentation
Late-breaking preclinical data on BBO-10203 presented at SABCS
breast cancersource ↗
●Poster PresentationBBO-10203Presentation
Preclinical data presented at AACR-NCI-EORTC 2025
multiple tumor typessource ↗
●Poster PresentationBBO-11818Presentation
Preclinical data presented at AACR-NCI-EORTC 2025
advanced solid tumorssource ↗
▲Equity OfferingCorporate
Helix Acquisition Corp. II retains ~$120M from trust; expects ~$382M gross proceeds from business combination with BBOT
◆Quarterly UpdateCorporate
Extraordinary General Meeting of Helix shareholders to vote on business combination
◆AcquisitionCorporate
Helix Acquisition Corp. II and BBOT announce effectiveness of registration statement for proposed business combination
▲First Patient DosedBBO-11818Trial
First patient dosed with BBO-11818 in Phase 1 trial
advanced solid tumorssource ↗
◆AcquisitionCorporate
Business combination agreement between BBOT and Helix Acquisition Corp. II announced
▲Fast Track DesignationBBO-8520Designation
FDA granted Fast Track designation to BBO-8520
previously treated, KRASG12C mutated metastatic non-small cell lung cancer (NSCLC)source ↗
Past FDA Catalysts and PDUFA Decisions
How BBOT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | BBO-10203 (first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction) | Phase 1a/1b data readout | Phase 1a/1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$236M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
0.8x
rNPV / MCap
Top 44%
Micro Cap(rank 290 of 658)
Percentile Rank
BridgeBio Oncology Therapeutics, Inc. faces pipeline headwinds (38/100), with $1.2B risk-adjusted pipeline value, led by BBO-11818 in Non-Small Cell Lung Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BBO-11818 Small moleculeNCT06917079 | Non-Small Cell Lung Cancer | Phase 1 | RECRUITING | 665 | Sep 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every BBOT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BBO-8520 | NSCLC | Phase 1 | 2026-09-08 | combination with pembrolizumab: ORR 75%, dose level 500 mg QD, overall ORR 53%, N 17; monotherapy: ORR 63%, patients 26/41, DCR 100%, patients DCR 41/41Read More | BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant CancersRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ben YongOfficer (Chief Med & Dev Officer) | Disposition | -1,047 44,576 held | $7.80 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BBOT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 1 % (-9.1 %) | 21.51 M | 2.82 M |
BBOT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BBOT ranks across every disease it competes in
Competitive Position is a premium feature
See how BBOT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBBOT News
BBOT▼ -23.8%on this news· ran to -43% by day 3
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
BridgeBio Oncology Therapeutics, Inc. (BBOT) announced promising clinical data for its KRAS G12C inhibitor, BBO-8520, showing a 75% objective response rate in combination with pembrolizumab for NSCLC patients. The company is prioritizing BBO-8520 and other combinations in KRAS-mutant cancers, supported by a robust financial position. Upcoming data catalysts are expected through mid-2027.
Read more →BBOTBBOT to Participate in Upcoming Investor Healthcare Conferences
BridgeBio Oncology Therapeutics, Inc. (BBOT) announced its participation in several upcoming investor healthcare conferences. The conferences include the Cantor Global Healthcare Conference, Citi's Biopharma Back to School Conference, and Morgan Stanley's Global Healthcare Conference. The leadership team will present and engage with investors, with webcasts available for later viewing.
Read more →BBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Oncology Therapeutics (BBOT) announced the awarding of inducement grants to two new employees as part of its 2025 Inducement Plan. The grants, consisting of non-qualified stock options for 65,350 shares, are intended to incentivize the new hires. This move reflects BBOT's strategy to enhance its workforce in the competitive biopharmaceutical sector.
Read more →BBOTBBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
BridgeBio Oncology Therapeutics (BBOT) reported its second quarter 2026 financial results, highlighting advancements in its clinical programs, including the initiation of dosing for BBO-11818 in combination therapies. The company presented promising preclinical data at AACR and reported a cash position that supports operations through 2028. However, BBOT also noted an increase in net loss and R&D expenses compared to the previous year.
Read more →BBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 12, 2026
BridgeBio Oncology Therapeutics (BBOT) announced the award of inducement grants to a new employee as part of its 2025 Inducement Plan. The grants include non-qualified stock options for 32,675 shares at an exercise price of $7.66, vesting over time contingent on continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and showcases BBOT's commitment to attracting talent.
Read more →BBOTBBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported its Q1 2026 financial results, highlighting progress in its RAS-pathway inhibitor programs. Notable developments include promising preliminary data for BBO-8520 and BBO-11818, with clinical readouts expected later in 2026. The company maintains a strong cash position, projected to support operations through 2028.
Read more →BBOTBBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
BridgeBio Oncology Therapeutics, Inc. presented promising preclinical data for BBO-11818, a pan-KRAS inhibitor, at the AACR Annual Meeting 2026. The data indicates significant anti-tumor activity in KRAS-mutant models, highlighting its potential as a monotherapy and in combination with other treatments. Updated Phase 1 clinical data is anticipated later in 2026.
Read more →BBOT▼ -6.2%on this news
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
BBOT has announced the appointments of Pedro J. Beltran, PhD, as the new Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman. This leadership change is intended to guide the company as it progresses into a new phase of development with its clinical assets moving towards pivotal trials for RAS and PI3K malignancies. The Board of Directors believes that these appointments reflect BBOT's dedication to improving patient outcomes and executing its strategic goals effectively.
Read more →BBOT▼ -6.2%on this newsshared move
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
BridgeBio Oncology Therapeutics, Inc. (BBOT) presented promising preclinical data for BBO-10203 at the AACR Annual Meeting 2026. This novel small molecule disrupts the RAS:PI3Kα interaction, inhibiting RAS-driven signaling without causing hyperglycemia. The data suggest BBO-10203 could effectively treat HER2 AMP tumors, with strong combination effects observed with HER2 inhibitors. Updated clinical data are anticipated in late 2026.
Read more →BBOTBBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
BridgeBio Oncology Therapeutics, Inc. announced that the FDA has granted Fast Track designation to BBO-11818 for treating advanced KRAS-mutant pancreatic ductal adenocarcinoma. This designation aims to expedite the development process for this promising therapy, which has shown preliminary efficacy in clinical trials. BBO-11818 is designed to address the unmet medical needs of patients with various KRAS mutations.
Read more →BBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 13, 2026
BridgeBio Oncology Therapeutics (BBOT) has awarded inducement grants to a new employee as part of its 2025 Inducement Plan. The grants include non-qualified stock options for 32,675 shares at an exercise price of $8.40, vesting over time contingent on continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects BBOT's strategy to enhance its workforce.
Read more →BBOT▼ -6.3%on this news
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
BridgeBio Oncology Therapeutics, Inc. (BBOT) announced multiple presentations at the AACR Annual Meeting 2026 in San Diego. The presentations will focus on their innovative therapies BBO-10203 and BBO-11818, targeting RAS-pathway malignancies. BBO-11818 is currently in a Phase 1 trial for KRAS-mutant solid tumors, while BBO-10203 is being evaluated for HER2+ breast cancer and other indications.
Read more →BBOTBBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
BBOT has published preclinical data on BBO-11818, a selective panKRAS inhibitor, demonstrating its efficacy against KRAS mutant cancers. The compound shows promising tumor growth inhibition and potential for combination therapies. Preliminary data from the ongoing Phase 1 KONQUER-101 trial indicates encouraging anti-tumor activity, with further updates expected in 2026.
Read more →BBOTBBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
BBOT has released its fourth quarter and full year 2025 financial results, highlighting a successful debut as a publicly traded oncology company. The company is advancing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. Encouraging preliminary data has been reported for these programs, with significant clinical readouts expected in late 2026. Furthermore, BBOT's robust cash position is projected to fund operations into 2028, supporting ongoing development efforts.
Read more →BBOT▼ -5.1%on this news
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 11, 2026
BridgeBio Oncology Therapeutics (BBOT) announced the awarding of inducement grants to two new employees as part of its 2025 Inducement Plan. The grants, which include non-qualified stock options for 65,350 shares, are intended to incentivize the new hires. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects BBOT's commitment to enhancing its workforce.
Read more →BBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - January 13, 2026
BridgeBio Oncology Therapeutics (BBOT) announced the awarding of inducement grants under its 2025 Inducement Plan. The grants were made to a new employee hired in December 2025, consisting of stock options for 129,090 shares at an exercise price of $13.19. These awards are part of BBOT's strategy to attract talent and were approved by the board's compensation committee.
Read more →BBOTBBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3K Pipeline Programs
BridgeBio Oncology Therapeutics (BBOT) announced positive preliminary data for its three RAS and PI3K pipeline programs, highlighting the potential of BBO-8520, BBO-11818, and BBO-10203. The data shows encouraging safety profiles and anti-tumor activity, particularly for BBO-8520, which may serve as a significant combination therapy with pembrolizumab. BBOT aims to address unmet needs in treating KRASG12C mutant NSCLC and plans to continue developing these therapies through advanced clinical trials.
Read more →BBOTBBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
BridgeBio Oncology Therapeutics, Inc. (BBOT) announced late-breaking preclinical data on BBO-10203, a novel RAS:PI3Kα breaker, at the San Antonio Breast Cancer Symposium. The data suggests that BBO-10203 can inhibit RAS-driven PI3Kα-AKT signaling without causing hyperglycemia. Additionally, the company will present a trial in progress poster for the Phase 1 BREAKER-101 study, which evaluates BBO-10203 in various cancer types.
Read more →BBOTBBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
BridgeBio Oncology Therapeutics, Inc. (BBOT) has released its third-quarter financial results for 2025, highlighting its recent Nasdaq debut and the appointment of Uneek Mehra as Chief Financial Officer. The company is advancing a promising pipeline targeting RAS and PI3K malignancies, with three clinical assets progressing toward important data readouts in 2026. Despite a reported net loss of $44,757, BBOT's financial position is projected to sustain operations until 2028. However, elevated operational expenses and the accumulated deficit signal ongoing financial hurdles.
Read more →About BridgeBio Oncology Therapeutics, Inc.
Headquarters256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next BBOT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime